| Sequence | TPLGIDLDEWSMATY |
|---|---|
| Purity | >90% (HPLC-MS) |
Application
| Cellular immune response, T-cell expansion, Antigen specific T-cell stimulation, Immune monitoring, T-cell assays |
| Primary Accession | P0DTD1 |
| Other Accession | R1AB_SARS2 |
| Gene ID | 43740578 |
|---|---|
| Other Names | Replicase polyprotein 1ab, pp1ab (ORF1ab polyprotein) [Cleaved into: Host translation inhibitor nsp1 (Leader protein) (Non-structural protein 1, nsp1); Non-structural protein 2, nsp2 (p65 homolog); Non-structural protein 3, nsp3, EC 3.4.19.12, EC 3.4.22.- (PL2-PRO) (Papain-like proteinase, PL-PRO); Non-structural protein 4, nsp4; 3C-like proteinase, 3CL-PRO, 3CLp, EC 3.4.22.69 (Main protease, Mpro) (Non-structural protein 5, nsp5) (SARS coronavirus main proteinase); Non-structural protein 6, nsp6; Non-structural protein 7, nsp7; Non-structural protein 8, nsp8; Non-structural protein 9, nsp9; Non-structural protein 10, nsp10 (Growth factor-like peptide, GFL); RNA-directed RNA polymerase, Pol, RdRp, EC 2.7.7.48 (Non-structural protein 12, nsp12); Helicase, Hel, EC 3.6.4.12, EC 3.6.4.13 (Non-structural protein 13, nsp13); Proofreading exoribonuclease, ExoN, EC 3.1.13.- (Guanine-N7 methyltransferase) (Non-structural protein 14, nsp14); Uridylate-specific endoribonuclease, EC 3.1.-.- (NendoU) (Non-structural protein 15, nsp15); 2'-O-methyltransferase, EC 2.1.1.- (Non-structural protein 16, nsp16) ] |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | rep |
|---|---|
| Function | Replicase polyprotein 1ab is a multifunctional protein involved in the transcription and replication of SARS-Cov-2 RNAs crucial to the viral life cycle. Contains the proteinases responsible for the cleavages of the polyprotein, including host translation inhibitor non-structural proteins nsp1, nsp2, nsp3, nsp4, nsp6, nsp7, nsp8, nsp9, nsp10, 3C-like proteinase, RNA-directed RNA polymerase, helicase, proofreading exoribonuclease, uridylate-specific endoribonuclease, and 2'-O-methyltransferase. |
| Cellular Location | Cleaved proteins localize in different host cellular compartments, including membrane, cytoplasm, virally-induced cytoplasmic double-membrane vesicles, perinuclear cytoplasmic foci, and endoplasmic reticulum-Golgi intermediate compartments. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@clinisciences.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
SARS-CoV-2 is part of the Coronaviridae family, whose members are named after their crown-like appearance under the electron microscope caused by the surface glycoproteins that decorate the virus. Coronaviruses have a large (30+ kb) single-stranded positivesense RNA genome encoding for several open reading frames. The open reading frame ORF1ab is the source for replicase, replicase/transcriptase, and polymerase polyproteins. ORF1ab is translated into ORF1a and ORF1b polyproteins in the host cell. Virus-encoded proteinases including 3C like protease cleaveORF1 into multiple nonstructural proteins (nsps). ORF1a yields protein products nsp 1 to nsp 10, which play at role in response to cellular stresses and maintaining integrity of the cellular components, along with crucial roles in viral replication. ORF1b encodes viral RNA-dependent RNA polymerase, helicase, exonuclease, auridylate specific endonuclease, and methyl transferase . THe significant contribution of these proteins to viral pathogenesis makes them promising targets for anti-viral therapeutics and vaccine development.